Oncolytics Biotech aligns with FDA on registrational path
Oncolytics Biotech (ONCY) says it has aligned with the FDA on the registrational path for second-line RAS-mutant MSS colorectal cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.